Athira Pharma (NASDAQ:LONA) Upgraded at Wall Street Zen

Athira Pharma (NASDAQ:LONA) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

Separately, Weiss Ratings initiated coverage on shares of Athira Pharma in a report on Wednesday. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Athira Pharma presently has a consensus rating of “Sell”.

Athira Pharma Stock Down 7.3%

Athira Pharma stock opened at $4.34 on Friday. Athira Pharma has a 12-month low of $2.20 and a 12-month high of $8.36.

Athira Pharma Company Profile

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.